Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

Abstract excerpt

Summary Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia ( ITP ) and a platelet count <30 × 10 9 /l (ClinicalTrials.gov identifier NCT 01438840). The...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood groups and transfusion
• Share to Blood properties and coagulation
• Share to Platelet Disorders and Treatments